2023
Modelling anticoagulation and health-related quality of life in those with atrial fibrillation: a secondary analysis of AFFIRM
Stulberg E, Delic A, Zheutlin A, Steinberg B, Yaghi S, Sharma R, de Havenon A. Modelling anticoagulation and health-related quality of life in those with atrial fibrillation: a secondary analysis of AFFIRM. Clinical Research In Cardiology 2023, 113: 1200-1210. PMID: 37962572, PMCID: PMC11785410, DOI: 10.1007/s00392-023-02335-9.Peer-Reviewed Original ResearchHealth-related qualityTime-varying confoundingAtrial fibrillationTime-varying covariatesSecondary analysisSelection biasAssociation of anticoagulationAssociation of warfarinAtrial Fibrillation FollowAge-stratified analysisLife substudyWarfarin useBetter HRQoLPrimary endpointTrial qualityHigher HRQoLStudy baselineEffect modificationStratified analysisAnticoagulationHRQoLInverse probabilityFibrillationStudy periodTime points
2017
Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial
Thomas R, Burger R, Harper A, Kanema S, Mwenge L, Vanqa N, Bell-Mandla N, Smith P, Floyd S, Bock P, Ayles H, Beyers N, Donnell D, Fidler S, Hayes R, Hauck K, Team H, Hargreaves J, Watson-Jones D, Godfrey-Faussett P, Cori A, Pickles M, Mandla N, Yang B, James A, Vermaak R, Makola N, Hoddinott G, Naidoo V, Bond V, Simwinga M, Mwinga A, Kosloff B, Limbada M, Bwalya J, Ngulube C, Fraser C, Eshleman S, Agyei Y, Cummings V, Catalano D, Emel L, Bunts L, Noble H, Burns D, Kouda A, Sista N, Moore A, White R, Headen T, Miller E, Hinson K, Vermund S, Barnes M, Horn L, Mwango A, Baldwin M, Wolf S, Hughes E. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. The Lancet Global Health 2017, 5: e1133-e1141. PMID: 28964756, PMCID: PMC5640509, DOI: 10.1016/s2214-109x(17)30367-4.Peer-Reviewed Original ResearchConceptsHIV-negative peopleHIV-positive individualsHIV-negative individualsAntiretroviral therapyHealth-related qualityHIV careHRQoL scoresHIV statusHerpes simplex virus type-2 statusNational InstituteHPTN 071 (PopART) studyHPTN 071 (PopART) trialLaboratory-confirmed HIVType 2 statusCross-sectional baseline surveyLarge cross-sectional surveyRecreational drug useCross-sectional surveyPresident's Emergency PlanGeneral population sampleHRQoL informationBetter HRQoLHIV-negativeHIV progressionHRQoL dataHealth-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.
De Wit R, Bajorin D, Bellmunt J, Fradet Y, Lee J, Fong L, Vogelzang N, Climent M, Petrylak D, Choueiri T, Necchi A, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, Mai Y, Li H, Perini R, Vaughn D. Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045. Journal Of Clinical Oncology 2017, 35: 4530-4530. DOI: 10.1200/jco.2017.35.15_suppl.4530.Peer-Reviewed Original ResearchAdvanced urothelial cancerGlobal health status/QoL scoreUrothelial cancerKEYNOTE-045HRQoL instrumentsQOL scoresWk 15Cox proportional hazards modelStratified log-rank testHRQOL end pointsSecond-line therapyTreatment-related AEsHealth-related qualityLog-rank testProportional hazards modelSuperior OSBetter HRQoLHRQoL analysisStudy treatmentPembroHazards modelInvestigator's choiceRate of improvementLongitudinal data analysis modelEnd pointHealth-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.
Vaughn D, Bellmunt J, De Wit R, Fradet Y, Lee J, Fong L, Vogelzang N, Climent M, Petrylak D, Choueiri T, Necchi A, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, Mai Y, Li H, Perini R, Bajorin D. Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. Journal Of Clinical Oncology 2017, 35: 282-282. DOI: 10.1200/jco.2017.35.6_suppl.282.Peer-Reviewed Original ResearchGlobal health status/QoL scoreAdvanced UCKEYNOTE-045HRQoL instrumentsQOL scoresWk 15Cox proportional hazards modelStratified log-rank testAdvanced urothelial cancerHRQOL end pointsInvestigator-choice chemotherapySecond-line therapyTreatment-related AEsHealth-related qualityLog-rank testProportional hazards modelSuperior OSBetter HRQoLHRQoL analysisUrothelial cancerStudy treatmentPembroHazards modelInvestigator's choiceRate of improvement
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply